Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Maya Katz, MD

    TitleAssistant Professor
    SchoolUCSF School of Medicine
    Address4150 Clement St.#219G
    San Francisco CA 94121
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      Cornell UniversityB.A.College of Arts and Sciences1999
      Cornell UniversityM.D.Weill Medical College 2007
      Mount Sinai Medical CenterResidencyNeurology2010
      Mount Sinai Medical CenterChief ResidentNeurology2011
      University of California,San FranciscoFellowshipMovement Disorders2013
      Collapse Awards and Honors
      2016Parkinson’s Disease Foundation Advancing Parkinson’s Therapies Conference Award
      2015Movement Disorders Society Fostering New Directions in Parkinson’s Research Award

      Collapse Overview 
      Collapse Overview
      Dr. Maya Katz is an Assistant Professor of Neurology at the UCSF Movement Disorders and Neuromodulation Center. She specializes in the treatment of Parkinson's disease, essential tremor, dystonia and other movement disorders. Her research interests include identifying disease modification strategies and improving outcomes for patients treated with deep brain stimulation. She is also interested in developing multidisciplinary clinical approaches that incorporate palliative care principles.

      Dr. Katz obtained her medical degree at Cornell University. She completed her residency in Neurology at Mount Sinai Medical Center, where she served as chief resident. She then completed her Movement Disorders Fellowship at UCSF in 2013. Dr. Katz is board certified in Neurology and is an active member of the American Academy of Neurology and the International Parkinson and Movement Disorder Society.

      Collapse ORNG Applications 
      Collapse Global Health

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Coleman RR, Starr PA, Katz M, Glass GA, Volz M, Khandhar SM, Ostrem JL. Bilateral Ventral Intermediate Nucleus Thalamic Deep Brain Stimulation in Orthostatic Tremor. Stereotact Funct Neurosurg. 2016; 94(2):69-74. PMID: 27002536.
        View in: PubMed
      2. Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemed J E Health. 2016 Jul; 22(7):590-8. PMID: 26886406.
        View in: PubMed
      3. Reyes RC, Cittolin-Santos GF, Kim JE, Won SJ, Brennan-Minnella AM, Katz M, Glass GA, Swanson RA. Erratum to: Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid. Neurotherapeutics. 2016 Jan; 13(1):239. PMID: 26659493.
        View in: PubMed
      4. Reyes RC, Cittolin-Santos GF, Kim JE, Won SJ, Brennan-Minnella AM, Katz M, Glass GA, Swanson RA. Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid. Neurotherapeutics. 2016 Jan; 13(1):217-25. PMID: 26572666.
        View in: PubMed
      5. Ostrem JL, Ziman N, Galifianakis NB, Starr PA, Luciano MS, Katz M, Racine CA, Martin AJ, Markun LC, Larson PS. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease. J Neurosurg. 2016 Apr; 124(4):908-16. PMID: 26495947.
        View in: PubMed
      6. Katz M, Luciano MS, Carlson K, Luo P, Marks WJ, Larson PS, Starr PA, Follett KA, Weaver FM, Stern MB, Reda DJ, Ostrem JL. Differential effects of deep brain stimulation target on motor subtypes in Parkinson's disease. Ann Neurol. 2015 Apr; 77(4):710-9. PMID: 25627340.
        View in: PubMed
      7. Katz M, Won SJ, Park Y, Orr A, Jones DP, Swanson RA, Glass GA. Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson's disease. Parkinsonism Relat Disord. 2015 May; 21(5):500-3. PMID: 25765302.
        View in: PubMed
      8. Chan YF, Katz M, Moskowitz A, Levine SR, Richardson LD, Tuhrim S, Chason K, Barsan-Silverman K, Singhal A. Supplemental oxygen delivery to suspected stroke patients in pre hospital and emergency department settings. Med Gas Res. 2014; 4:16. PMID: 26413266; PMCID: PMC4582959.
      9. Katz M, Byl NN, San Luciano M, Ostrem JL. Focal task-specific lower extremity dystonia associated with intense repetitive exercise: a case series. Parkinsonism Relat Disord. 2013 Nov; 19(11):1033-8. PMID: 23932354.
        View in: PubMed
      10. Cheung T, Nuño M, Hoffman M, Katz M, Kilbane C, Alterman R, Tagliati M. Longitudinal impedance variability in patients with chronically implanted DBS devices. Brain Stimul. 2013 Sep; 6(5):746-51. PMID: 23619246.
        View in: PubMed
      11. Bryson EO, Aloysi AS, Katz M, Popeo D, Kellner CH. Rocuronium as muscle relaxant for electroconvulsive therapy in a patient with adult-onset muscular dystrophy. J ECT. 2011 Dec; 27(4):e63-4. PMID: 22124227.
        View in: PubMed
      12. Katz M, Kilbane C, Rosengard J, Alterman RL, Tagliati M. Referring patients for deep brain stimulation: an improving practice. Arch Neurol. 2011 Aug; 68(8):1027-32. PMID: 21825238.
        View in: PubMed
      13. Dumont M, Kipiani K, Yu F, Wille E, Katz M, Calingasan NY, Gouras GK, Lin MT, Beal MF. Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2011; 27(1):211-23. PMID: 21799249; PMCID: PMC3267988.
      Maya's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP